{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 464390046
| type              = mab
| image             = Sifalimumab 4YPG.png
| caption           = [[Fab fragment]] of sifalimumab bound to IFN-Î±2A. From {{PDB|4ypg}}.
| alt               = 
| mab_type          = mab
| source            = u
| target            = [[Interferon alfa|Interferon &alpha;]]
| tradename         =  
| Drugs.com         =
| MedlinePlus       =
| pregnancy_AU      = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US      = <!-- A / B            / C / D / X -->
| pregnancy_category=  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status      = 
| routes_of_administration = 
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| elimination_half-life = 
| excretion         = 
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number        = 1143503-67-6
| ATC_prefix        = none
| ATC_suffix        = 
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = XOY1YA7RMC
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| PubChem           = 
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank          =
| KEGG = D09668
| C=6518 | H=10008 | N=1724 | O=2032 | S=38
| molecular_weight = 146.25 kg/mol
}}

'''Sifalimumab''' is a human monoclonal antibody designed for the treatment of [[Systemic lupus erythematosus|SLE]], [[dermatomyositis]], and [[polymyositis]]. It targets interferon a.<ref>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Sifalimumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/sifalimumab.pdf}}</ref>

Sifalimumab was developed by [[MedImmune]]; as of 2017 development had been terminated in favor of moving a competing internal product, [[anifrolumab]], into Phase III trials.<ref>{{cite web|title=Press release: New Hope for Lupus Patients|url=https://www.medimmune.com/about-us/media/new-hope-for-lupus-patients-20150811.html|publisher=MedImmune|archiveurl=https://web.archive.org/web/20170731052844/https://www.medimmune.com/about-us/media/new-hope-for-lupus-patients-20150811.html|archivedate=31 July 2017|language=en|date=11 August 2015}}</ref><ref>{{cite web|title=Sifalimumab|url=http://adisinsight.springer.com/drugs/800024071|publisher=AdisInsight|accessdate=31 July 2017|language=en}}</ref><ref>{{cite web|title=Sifalimumab|url=https://www.sps.nhs.uk/medicines/sifalimumab/|publisher=NHS Specialist Pharmacy Service|accessdate=31 July 2017}}</ref>

== References ==
<references/>


{{Monoclonals for immune system}}
{{Cytokine receptor modulators}}

[[Category:Monoclonal antibodies]]


{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}